{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T21:07:30Z","timestamp":1788815250437,"version":"build-2803163510"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["canadianjournalofophthalmology.ca","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Canadian Journal of Ophthalmology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.jcjo.2026.08.002","type":"journal-article","created":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T20:11:46Z","timestamp":1788811906000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical and MRI outcomes of teprotumumab in Japanese thyroid eye disease"],"prefix":"10.1016","author":[{"given":"Muhammad","family":"Abumanhal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mizuki","family":"Tagami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taichi","family":"Higashida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gen","family":"Kinari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1363-2870","authenticated-orcid":false,"given":"Yasuhiro","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcjo.2026.08.002_bib0001","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1038\/s41433-018-0302-1","article-title":"Clinical pathophysiology of thyroid eye disease: the cone model","volume":"33","author":"Meyer","year":"2019","journal-title":"Eye (Lond)."},{"key":"10.1016\/j.jcjo.2026.08.002_bib0002","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.autrev.2014.01.013","article-title":"Diagnosis and classification of Graves' disease","volume":"13","author":"Menconi","year":"2014","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.jcjo.2026.08.002_bib0003","series-title":"Dysthyroid Optic Neuropathy","author":"Agarwal","year":"2022"},{"key":"10.1016\/j.jcjo.2026.08.002_bib0004","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1507\/endocrj.EJ16-0083","article-title":"Comparison of two different regimens of intravenous methylprednisolone for patients with moderate to severe and active Graves' ophthalmopathy: a prospective, randomized controlled trial","volume":"64","author":"He","year":"2017","journal-title":"Endocr J"},{"key":"10.1016\/j.jcjo.2026.08.002_bib0005","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1007\/s00417-016-3280-7","article-title":"Efficacy of combined orbital radiation and systemic steroids in the management of Graves' orbitopathy","volume":"254","author":"Kim","year":"2016","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.jcjo.2026.08.002_bib0006","doi-asserted-by":"crossref","DOI":"10.1177\/11795514261426446","article-title":"Pharmacologic therapies for active moderate-to-severe TED: a comprehensive systematic review","volume":"19","author":"Builes-Monta\u00f1o","year":"2026","journal-title":"Clin Med Insights Endocrinol Diabetes"},{"key":"10.1016\/j.jcjo.2026.08.002_bib0007","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1056\/NEJMoa1614949","article-title":"Teprotumumab for thyroid-associated ophthalmopathy","volume":"376","author":"Smith","year":"2017","journal-title":"N Engl J Med"},{"issue":"suppl 1","key":"10.1016\/j.jcjo.2026.08.002_bib0008","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1159\/000507992","article-title":"Teprotumumab treatment for thyroid-associated ophthalmopathy","volume":"9","author":"Smith","year":"2020","journal-title":"Eur Thyroid J"},{"key":"10.1016\/j.jcjo.2026.08.002_bib0009","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1210\/endrev\/bnae018","article-title":"Teprotumumab for the treatment of thyroid eye disease","volume":"45","author":"Ugradar","year":"2024","journal-title":"Endocr Rev"},{"key":"10.1016\/j.jcjo.2026.08.002_bib0010","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/S2213-8587(21)00056-5","article-title":"Teprotumumab for patients with active thyroid eye disease: a pooled data analysis, subgroup analyses, and off-treatment follow-up results from two randomised, double-masked, placebo-controlled, multicentre trials","volume":"9","author":"Kahaly","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.jcjo.2026.08.002_bib0011","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s00417-024-06599-3","article-title":"Teprotumumab for thyroid eye disease in patients with hypothyroid\/euthyroid state: a multicenter case series","volume":"263","author":"Ugradar","year":"2025","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.jcjo.2026.08.002_bib0012","article-title":"A randomised, double-masked, placebo-controlled trial evaluating the efficacy and safety of teprotumumab for active thyroid eye disease in Japanese patients","volume":"55","author":"Hiromatsu","year":"2025","journal-title":"Lancet Reg Health West Pac"},{"key":"10.1016\/j.jcjo.2026.08.002_bib0013","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1097\/WNO.0000000000001994","article-title":"Real-world experience with teprotumumab in patients with dysthyroid optic neuropathy","volume":"44","author":"Tamhankar","year":"2024","journal-title":"J Neuroophthalmol"},{"key":"10.1016\/j.jcjo.2026.08.002_bib0014","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.4103\/ijo.IJO_365_22","article-title":"Magnetic resonance imaging in thyroid eye disease: signal intensity ratio to measure disease activity","volume":"70","author":"Rath","year":"2022","journal-title":"Indian J Ophthalmol"},{"key":"10.1016\/j.jcjo.2026.08.002_bib0015","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/eye.2001.102","article-title":"Serial STIR magnetic resonance imaging correlates with clinical score of activity in thyroid disease","volume":"15","author":"Mayer","year":"2001","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.jcjo.2026.08.002_bib0016","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1136\/bjophthalmol-2020-317806","article-title":"Teprotumumab reduces extraocular muscle and orbital fat volume in thyroid eye disease","volume":"106","author":"Jain","year":"2022","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.jcjo.2026.08.002_bib0017","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1097\/IOP.0000000000002337","article-title":"Reduction in extraocular muscle cross-sectional area and correlation with extraocular motility and diplopia following teprotumumab for thyroid eye disease","volume":"39","author":"Reshef","year":"2023","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"10.1016\/j.jcjo.2026.08.002_bib0018","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1097\/IOP.0000000000002867","article-title":"Clinical and radiologic predictors of response to teprotumumab: a 3D volumetric analysis of 35 patients","volume":"41","author":"Ugradar","year":"2025","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"10.1016\/j.jcjo.2026.08.002_bib0019","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/S0002-9394(14)72787-4","article-title":"Diagnostic criteria for Graves' ophthalmopathy","volume":"119","author":"Bartley","year":"1995","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.jcjo.2026.08.002_bib0020","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1007\/s00417-022-05827-y","article-title":"Risk factors for development of superior limbic keratoconjunctivitis in thyroid eye disease in Japanese","volume":"261","author":"Takahashi","year":"2023","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.jcjo.2026.08.002_bib0021","unstructured":"The Japanese Committee for Diagnostic Criteria and Guideline to Medical Care for Thyroid-Associated Malignant Exophthalmos. The guideline for treatment of thyroid eye disease 2023.https:\/\/www.j-endo.jp\/uploads\/files\/edu\/koujyousengansyo_3.pdf; 2023. (accessed May 13, 2026)."},{"key":"10.1016\/j.jcjo.2026.08.002_bib0022","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1097\/IIO.0000000000000452","article-title":"Diagnosis and management of dysthyroid optic neuropathy","volume":"63","author":"Takahashi","year":"2023","journal-title":"Int Ophthalmol Clin"},{"key":"10.1016\/j.jcjo.2026.08.002_bib0023","unstructured":"The Japanese Ophthalmological Society. Definition of visual impairment and standard visual acuity examination.https:\/\/www.nichigan.or.jp\/Portals\/0\/images\/member\/journal\/terms\/appendix_1.pdf. (accessed May 12, 2026)."},{"key":"10.1016\/j.jcjo.2026.08.002_bib0024","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1136\/bjo.73.8.639","article-title":"Clinical criteria for the assessment of disease activity in Graves' ophthalmopathy: a novel approach","volume":"73","author":"Mourits","year":"1989","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.jcjo.2026.08.002_bib0025","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1038\/s41598-019-38640-5","article-title":"Predictive factors of prognosis after radiation and steroid pulse therapy in thyroid eye disease","volume":"9","author":"Ito","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.jcjo.2026.08.002_bib0026","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1097\/OPX.0b013e3181ce5702","article-title":"Proptosis in dysthyroid ophthalmopathy: a case series of 10,931 Japanese cases","volume":"87","author":"Kozaki","year":"2010","journal-title":"Optom Vis Sci"},{"key":"10.1016\/j.jcjo.2026.08.002_bib0027","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1177\/10507256251359559","article-title":"Clinical features of Chinese patients with thyroid eye disease: a multicenter retrospective study","volume":"35","author":"Lei","year":"2025","journal-title":"Thyroid"},{"key":"10.1016\/j.jcjo.2026.08.002_bib0028","doi-asserted-by":"crossref","first-page":"G43","DOI":"10.1530\/EJE-21-0479","article-title":"The 2021 European Group on Graves' orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves' orbitopathy","volume":"185","author":"Bartalena","year":"2021","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.jcjo.2026.08.002_bib0029","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.3390\/diagnostics16101521","article-title":"A pilot MRI study of upward gaze-induced intraocular pressure elevation in thyroid eye disease","volume":"16","author":"Abumanhal","year":"2026","journal-title":"Diagnostics (Basel)"},{"key":"10.1016\/j.jcjo.2026.08.002_bib0030","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1007\/s00417-023-06013-4","article-title":"Early response to intravenous methylprednisolone therapy for restrictive myopathy in patients with thyroid eye disease","volume":"261","author":"Jang","year":"2023","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.jcjo.2026.08.002_bib0031","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1001\/jamaophthalmol.2021.6284","article-title":"Proptosis and diplopia response with teprotumumab and placebo vs the recommended treatment regimen with intravenous methylprednisolone in moderate to severe thyroid eye disease: a meta-analysis and matching-adjusted indirect comparison","volume":"140","author":"Douglas","year":"2022","journal-title":"JAMA Ophtalmol"},{"key":"10.1016\/j.jcjo.2026.08.002_bib0032","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1038\/s41433-023-02856-7","article-title":"Dysthyroid optic neuropathy: a case series at a tertiary ophthalmic referral centre","volume":"38","author":"Chung","year":"2024","journal-title":"Eye"},{"key":"10.1016\/j.jcjo.2026.08.002_bib0033","article-title":"Quantitative magnetic resonance imaging biomarkers in the evaluation of disease activity in thyroid eye disease: a retrospective study","volume":"18","author":"Marston","year":"2026","journal-title":"Cureus"},{"key":"10.1016\/j.jcjo.2026.08.002_bib0034","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1136\/bjo-2024-325346","article-title":"Low clinical activity score, 'progressive' thyroid eye disease: presentations of 1439 patients from a tertiary centre in Hong Kong","volume":"109","author":"Lai","year":"2025","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.jcjo.2026.08.002_bib0035","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1007\/s40123-026-01326-z","article-title":"Management of thyroid eye disease: a comparison between three recent clinical guidelines","volume":"15","author":"Lei","year":"2026","journal-title":"Ophthalmol Ther"},{"key":"10.1016\/j.jcjo.2026.08.002_bib0036","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1016\/j.eprac.2024.08.005","article-title":"Effects of teprotumumab and role of human leukocyte antigens markers in patients with thyroid eye disease","volume":"30","author":"Hoang","year":"2024","journal-title":"Endocr Pract"},{"key":"10.1016\/j.jcjo.2026.08.002_bib0037","doi-asserted-by":"crossref","first-page":"e654","DOI":"10.1210\/clinem\/dgad213","article-title":"The adverse effects profile of teprotumumab","volume":"108","author":"Stan","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jcjo.2026.08.002_bib0038","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.ophtha.2023.10.018","article-title":"Teprotumumab-related adverse events in thyroid eye disease: a multicenter study","volume":"131","author":"Shah","year":"2024","journal-title":"Ophthalmology"}],"container-title":["Canadian Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0008418226002784?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0008418226002784?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T20:11:50Z","timestamp":1788811910000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0008418226002784"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":38,"alternative-id":["S0008418226002784"],"URL":"https:\/\/doi.org\/10.1016\/j.jcjo.2026.08.002","relation":{},"ISSN":["0008-4182"],"issn-type":[{"value":"0008-4182","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical and MRI outcomes of teprotumumab in Japanese thyroid eye disease","name":"articletitle","label":"Article Title"},{"value":"Canadian Journal of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcjo.2026.08.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Canadian Ophthalmological Society. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}